Preface: Chemical carcinogenesis in mice as a model of human cancer: Pros and cons.

[1]  L. Zitvogel,et al.  Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors , 2020, Nature Reviews Clinical Oncology.

[2]  L. Galluzzi,et al.  Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy , 2020, Nature Immunology.

[3]  O. Elemento,et al.  Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer , 2020, Nature Communications.

[4]  T. Kondo.  Current status and perspectives of patient-derived rare cancer models , 2020, Human Cell.

[5]  A. Wesa,et al.  Establishment of Humanized Mice from Peripheral Blood Mononuclear Cells or Cord Blood CD34+ Hematopoietic Stem Cells for Immune‐Oncology Studies Evaluating New Therapeutic Agents , 2020, Current protocols in pharmacology.

[6]  S. Arron,et al.  Tumour predisposition and cancer syndromes as models to study gene–environment interactions , 2020, Nature Reviews Cancer.

[7]  M. Esteller,et al.  The DNA methylation landscape of human cancer organoids available at the American type culture collection , 2020, Epigenetics.

[8]  F. Marincola,et al.  Consensus guidelines for the definition, detection and interpretation of immunogenic cell death , 2020, Journal for ImmunoTherapy of Cancer.

[9]  Jun Yu,et al.  Organoid models of gastrointestinal cancers in basic and translational research , 2020, Nature Reviews Gastroenterology & Hepatology.

[10]  U. Alon,et al.  Tumour heterogeneity and the evolutionary trade-offs of cancer , 2020, Nature Reviews Cancer.

[11]  A. Azmi,et al.  KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne? , 2020, Cancer treatment reviews.

[12]  L. Wessels,et al.  Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system , 2020, Oncoimmunology.

[13]  S. Ro,et al.  Genetically Engineered Mouse Models for Liver Cancer , 2019, Cancers.

[14]  N. Chen,et al.  Discovery of a covalent inhibitor of KRASG12C (AMG 510) for the treatment of solid tumors. , 2019, Journal of medicinal chemistry.

[15]  P. Lollini,et al.  Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model , 2019, Cancers.

[16]  F. Ginhoux,et al.  Engineered niches support the development of human dendritic cells in humanized mice , 2019, bioRxiv.

[17]  S. Chang,et al.  Targeting ST2 expressing activated regulatory T cells in Kras-mutant lung cancer , 2019, Oncoimmunology.

[18]  Ludovic C. Gillet,et al.  Quantitative Proteome Landscape of the NCI-60 Cancer Cell Lines , 2019, iScience.

[19]  O. Elemento,et al.  Organotypic tumor slice cultures provide a versatile platform for immuno-oncology and drug discovery , 2019, Oncoimmunology.

[20]  J. Desai,et al.  The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity , 2019, Nature.

[21]  I. Noorani.  Genetically Engineered Mouse Models of Gliomas: Technological Developments for Translational Discoveries , 2019, Cancers.

[22]  Shakkaura Kemet.  Insight Medicine Lacks - The Continuing Relevance of Henrietta Lacks. , 2019, The New England journal of medicine.

[23]  L. Galluzzi,et al.  Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients , 2019, Oncoimmunology.

[24]  H. Clevers,et al.  Xenograft and organoid model systems in cancer research , 2019, The EMBO journal.

[25]  C. López-Otín,et al.  Decelerating ageing and biological clocks by autophagy , 2019, Nature Reviews Molecular Cell Biology.

[26]  P. Meltzer,et al.  RNA sequencing of the NCI-60: Integration into CellMiner and CellMiner CDB. , 2019, Cancer research.

[27]  L. Galluzzi,et al.  Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy. , 2019, Trends in cell biology.

[28]  T. Goldmann,et al.  Interleukin-1β provided by KIT-competent mast cells is required for KRAS-mutant lung adenocarcinoma , 2019, Oncoimmunology.

[29]  K. Odunsi,et al.  Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer , 2019, Oncoimmunology.

[30]  H. Nishikawa,et al.  Regulatory T cells in cancer immunosuppression — implications for anticancer therapy , 2019, Nature Reviews Clinical Oncology.

[31]  D. Ingber,et al.  Modelling cancer in microfluidic human organs-on-chips , 2019, Nature Reviews Cancer.

[32]  C. Chougnet,et al.  Improved multilineage human hematopoietic reconstitution and function in NSGS mice , 2018, PloS one.

[33]  M. Smyth,et al.  Cancer immunoediting and resistance to T cell-based immunotherapy , 2018, Nature Reviews Clinical Oncology.

[34]  Huiyang Zhou,et al.  Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments , 2018, PloS one.

[35]  Timothy A. Chan,et al.  The hallmarks of successful anticancer immunotherapy , 2018, Science Translational Medicine.

[36]  L. Galluzzi,et al.  Modeling Tumor Immunology and Immunotherapy in Mice. , 2018, Trends in cancer.

[37]  Christopher J Kemp,et al.  Personalized Cancer Models for Target Discovery and Precision Medicine. , 2018, Trends in cancer.

[38]  H. Clevers,et al.  Organoids in cancer research , 2018, Nature Reviews Cancer.

[39]  A. Harris,et al.  Non-angiogenic tumours and their influence on cancer biology , 2018, Nature Reviews Cancer.

[40]  M. Disis.  Movie Review of The Immortal Life of Henrietta Lacks. , 2017, JAMA.

[41]  Bon-Kyoung Koo,et al.  Human Primary Liver Cancer -derived Organoid Cultures for disease modelling and drug screening , 2017, Nature Medicine.

[42]  Hellmut G. Augustin,et al.  Preclinical mouse solid tumour models: status quo, challenges and perspectives , 2017, Nature Reviews Cancer.

[43]  Anang A. Shelat,et al.  Orthotopic Patient-Derived Xenografts of Pediatric Solid Tumors , 2017, Nature.

[44]  C. N. Coleman,et al.  DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity , 2017, Nature Communications.

[45]  L. Galluzzi,et al.  DNA Damage in Stem Cells. , 2017, Molecular cell.

[46]  O. Ogawa,et al.  Patient-derived xenografts as in vivo models for research in urological malignancies , 2017, Nature Reviews Urology.

[47]  Michael L. Wang,et al.  B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy , 2017, Clinical Cancer Research.

[48]  E. A. Fry,et al.  Oncogenic and tumor‐suppressive mouse models for breast cancer engaging HER2/neu , 2017, International journal of cancer.

[49]  Hans Clevers,et al.  Interrogating open issues in cancer precision medicine with patient-derived xenografts , 2017, Nature Reviews Cancer.

[50]  Yaqing Huang,et al.  Investigation of Cross-Contamination and Misidentification of 278 Widely Used Tumor Cell Lines , 2017, PloS one.

[51]  Simon J. Dovedi,et al.  Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery , 2016, Cancer Immunology Research.

[52]  L. Zitvogel,et al.  Immunological Mechanisms Underneath the Efficacy of Cancer Therapy , 2016, Cancer Immunology Research.

[53]  Laurence Zitvogel,et al.  Mouse models in oncoimmunology , 2016, Nature Reviews Cancer.

[54]  M. Abba,et al.  DMBA induced mouse mammary tumors display high incidence of activating Pik3caH1047 and loss of function Pten mutations , 2016, Oncotarget.

[55]  Carlos López-Otín,et al.  Metabolic Control of Longevity , 2016, Cell.

[56]  F. Di Virgilio,et al.  Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. , 2016, Cancer cell.

[57]  Hans Clevers,et al.  Modeling pancreatic cancer with organoids. , 2016, Trends in cancer.

[58]  R. Flavell,et al.  Humanized hemato-lymphoid system mice , 2016, Haematologica.

[59]  L. Zitvogel,et al.  Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. , 2015, Cancer cell.

[60]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[61]  H. Greely,et al.  The Henrietta Lacks legacy grows , 2013, EMBO reports.

[62]  L. Galluzzi,et al.  Tumor-Infiltrating Regulatory T Cells: Phenotype, Role, Mechanism of Expansion In Situ and Clinical Significance , 2013, Cancer Microenvironment.

[63]  Manuel Serrano,et al.  The Hallmarks of Aging , 2013, Cell.

[64]  R. Flavell,et al.  Human hemato-lymphoid system mice: current use and future potential for medicine. , 2013, Annual review of immunology.

[65]  G. Colditz,et al.  Prostate cancer: is it time to expand the research focus to early-life exposures? , 2013, Nature Reviews Cancer.

[66]  D. Greiner,et al.  Humanized mice for immune system investigation: progress, promise and challenges , 2012, Nature Reviews Immunology.

[67]  V. Tybulewicz,et al.  Genomically humanized mice: technologies and promises , 2011, Nature Reviews Genetics.

[68]  V. Anisimov,et al.  Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice , 2011, Cell cycle.

[69]  L. Galluzzi,et al.  Illicit survival of cancer cells during polyploidization and depolyploidization , 2011, Cell Death and Differentiation.

[70]  L. Galluzzi,et al.  Hormesis, cell death and aging , 2011, Aging.

[71]  R. Flavell,et al.  Improving human hemato-lymphoid-system mice by cytokine knock-in gene replacement. , 2011, Trends in immunology.

[72]  C. Sonnenschein,et al.  Environmental causes of cancer: endocrine disruptors as carcinogens , 2010, Nature Reviews Endocrinology.

[73]  American Type Culture Collection Standards Development Orga ASN-0002.  Cell line misidentification: the beginning of the end , 2010, Nature Reviews Cancer.

[74]  Gabriele Bergers,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[75]  R. Schreiber,et al.  The three Es of cancer immunoediting. , 2004, Annual review of immunology.

[76]  Fuad G. Gwadry,et al.  Comparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cells , 2003, Genome Biology.

[77]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[78]  R. Schreiber,et al.  IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.

[79]  R. Schreiber,et al.  Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice , 1998 .

[80]  K. Palucka,et al.  Techniques for the generation of humanized mouse models for immuno-oncology. , 2020, Methods in enzymology.

[81]  A. Alice,et al.  Activating the Nucleic Acid-Sensing Machinery for Anticancer Immunity. , 2019, International review of cell and molecular biology.

[82]  K. Radford,et al.  The role of dendritic cells in cancer. , 2019, International review of cell and molecular biology.

[83]  Ton N Schumacher,et al.  Cancer Neoantigens. , 2019, Annual review of immunology.

[84]  M. Maiuri,et al.  Organoids for Modeling Genetic Diseases. , 2018, International review of cell and molecular biology.